An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Diagnosis: Multiple Myeloma
NCT ID: NCT01833039
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 13-307
The purpose of this study is to provide patients who have relapsed or refractory Mantle Cell Lymphoma (MCL) with early access to an investigational medication called ibrutinib (PCI-32765) and to collect safety information about the drug.
Massachusetts General Hospital
Jeffery Barnes, MD,
Dana Farber Cancer Institute
Massachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100
- Patients, 18 years of age and older, with Mantle Cell Lymphoma who have progressive
disease after prior therapy are eligible.
- Patients eligible for enrollment in any other ongoing clinical study of ibrutinib are
- Patients previously treated with ibrutinib are not eligible.
- Patients enrolled in another interventional clinical study with therapeutic intent
are not eligible.